Next Article in Journal
Microplastics in Airborne Particulate Matter: A Comprehensive Review of Separation Techniques, In Vitro Toxicity and Health Impacts
Previous Article in Journal
EZH2 Inhibition in Mesothelioma Cells Increases the Release of Extracellular Vesicles That Skew Neutrophils Toward a Protumor Phenotype
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma

1
Advanced Biomedical Research Lab, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Gyeonggi-do, Republic of Korea
2
Department of Advanced Drug Discovery & Development, Institut Pasteur Korea (IPK) School, University of Science and Technology (UST), 16, Daewangpangyo-ro 712 Beon-gil, Bundang-gu, Seongnam-si 13488, Gyeonggi-do, Republic of Korea
3
Department for Bio- and Nanotechnology, Fraunhofer Institute for Ceramic Technologies and Systems (IKTS), Perlickstr. 1, 04103 Leipzig, Germany
4
Department for Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstr. 1, 04103 Leipzig, Germany
5
H&O Biosis Co., Ltd., 19-10, Jeongnamsandan-ro, Jeongnam-myeon, Hwaseong-si 18514, Gyeonggi-do, Republic of Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2025, 26(21), 10329; https://doi.org/10.3390/ijms262110329
Submission received: 20 August 2025 / Revised: 15 October 2025 / Accepted: 19 October 2025 / Published: 23 October 2025
(This article belongs to the Section Molecular Oncology)

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the liver. Characterized by rapid progression and poor overall survival rates, HCC requires effective and streamlined treatment regimens. It predominantly occurs in East Asia and sub-Saharan Africa, where it has historically been managed with herbal formulas. We previously observed that the herbal formula HO-1089 exerts potent anti-HCC effects both in vitro and in vivo. In this study, we investigated the anticancer efficacy and mechanisms of HO-1197, a reconstituted herbal formulation derived from HO-1089. HO-1197 selectively inhibited the viability of HCC cell lines without hepatotoxicity and demonstrated superior anticancer activity compared with both HO-1089 and sorafenib. Mechanistically, HO-1197 induced apoptosis and G2/M arrest through reactive oxygen species-mediated DNA damage, independent of p53 status. Transcriptomic analysis revealed downregulation of mitosis-related genes, particularly those regulated by FOXM1, a key driver of HCC proliferation and metastasis. HO-1197 suppressed FOXM1 expression and nuclear translocation, reducing its downstream targets and diminishing angiogenic and metastatic potential. Furthermore, HO-1197 modulated the tumor immune microenvironment by promoting pro-inflammatory macrophage polarization and enhancing natural killer cell-mediated cytotoxicity. HO-1197 exhibited potent antitumor efficacy, and combination therapy with HO-1197 and sorafenib exhibited synergistic effects in both two-dimensional and immune-activated multicellular spheroid models. These findings suggest that HO-1197 is a promising multifunctional therapeutic candidate with antitumor, antiangiogenic, antimetastatic, and immunomodulatory properties. Its combination with sorafenib may offer effective treatment for HCC. HO-1197, which demonstrated strong efficacy, is a novel herbal medicine developed by H&O Biosis and is referred to as an Integrated Natural Medicine.
Keywords: hepatocellular carcinoma (HCC); cell cycle arrest; FOXM1; angiogenesis; metastasis; immune modulation hepatocellular carcinoma (HCC); cell cycle arrest; FOXM1; angiogenesis; metastasis; immune modulation

Share and Cite

MDPI and ACS Style

Song, Y.; Lee, S.; Heo, S.-W.; Spohn, J.; Schmiedel, D.; Heo, T.; Kim, S.; Park, J.; Seo, H.R. HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2025, 26, 10329. https://doi.org/10.3390/ijms262110329

AMA Style

Song Y, Lee S, Heo S-W, Spohn J, Schmiedel D, Heo T, Kim S, Park J, Seo HR. HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2025; 26(21):10329. https://doi.org/10.3390/ijms262110329

Chicago/Turabian Style

Song, Yeonhwa, Seungeun Lee, So-Won Heo, Juliane Spohn, Dominik Schmiedel, Taemoo Heo, Sanghwa Kim, Jongmin Park, and Haeng Ran Seo. 2025. "HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma" International Journal of Molecular Sciences 26, no. 21: 10329. https://doi.org/10.3390/ijms262110329

APA Style

Song, Y., Lee, S., Heo, S.-W., Spohn, J., Schmiedel, D., Heo, T., Kim, S., Park, J., & Seo, H. R. (2025). HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 26(21), 10329. https://doi.org/10.3390/ijms262110329

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop